Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Non-cash Items (2016)

Avalo Therapeutics filings provide 2 years of Non-cash Items readings, the most recent being $657099.0 for Q3 2016.

On a quarterly basis, Non-cash Items rose 49.47% to $657099.0 in Q3 2016 year-over-year; TTM through Sep 2016 was $657099.0, a 49.47% increase, with the full-year FY2015 number at $604167.0, changed N/A from a year prior.
Non-cash Items hit $657099.0 in Q3 2016 for Avalo Therapeutics, up from $642541.0 in the prior quarter.
In the past five years, Non-cash Items ranged from a high of $657099.0 in Q3 2016 to a low of $439607.0 in Q3 2015.